Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2009 1
2010 1
2011 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Ferrario A, Merli F, Luminari S, Stelitano C, Mannina D, Russo M, Mazza P, Marcheselli L, Goldaniga MC, Federico M, Baldini L; Gruppo Italiano per lo Studio dei Linfomi. Ferrario A, et al. Ann Hematol. 2011 Mar;90(3):323-30. doi: 10.1007/s00277-010-1067-1. Epub 2010 Sep 17. Ann Hematol. 2011. PMID: 20848104 Clinical Trial.
Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy.
Morabito F, Baldini L, Stelitano C, Luminari S, Frassoldati A, Merli F, Colombi M, Sabbatini R, Brugiatelli M, Federico M; Gruppo Italiano per lo studio dei linfomi. Morabito F, et al. Leuk Lymphoma. 2002 Oct;43(10):1933-8. doi: 10.1080/1042819021000016050. Leuk Lymphoma. 2002. PMID: 12481887
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Federico M, et al. J Clin Oncol. 2009 Feb 10;27(5):805-11. doi: 10.1200/JCO.2008.17.0910. Epub 2009 Jan 5. J Clin Oncol. 2009. PMID: 19124807 Clinical Trial.
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi.
Baldini L, Brugiatelli M, Luminari S, Lombardo M, Merli F, Sacchi S, Gobbi P, Liberati M, Cavanna L, Colombi M, Stelitano C, Goldaniga M, Morabito F, Federico M, Silingardi V; Gruppo Italiano per lo Studio dei Linfomi. Baldini L, et al. J Clin Oncol. 2003 Apr 15;21(8):1459-65. doi: 10.1200/JCO.2003.07.133. J Clin Oncol. 2003. PMID: 12697867 Clinical Trial.